Tag: Biocad

BIOCAD is Russia’s leading innovative biotechnology company which combines a world-class research and development center, ultra-modern pharmaceutical and biotechnology manufacturing facilities, and pre-clinical and clinical research infrastructure compliant with international standards.

BIOCAD is one of the few world’s full-cycle drug development and manufacturing companies, doing everything from new molecules discovery and genetic engineering to large-scale commercial manufacturing and marketing support. BIOCAD’s medicines are used to treat the most complex health conditions, such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.

The company employs about 1000 people, 300 out of them scientists and researchers. In 2014 BIOCAD’s sales tripled and reached $200 million, while total amount of long-term international contracts exceeded half a billion US dollars. BIOCAD has subsidiaries in the US, Brazil, China, India, Singapore, and other countries.

BIOCAD has established a wide international presence – through a network of its subsidiaries and partnerships – in Belarus, Ukraine, Brazil, India, China and the United States. BIOCAD’s international strategy is to reinforce its own market leadership position in Russia while entering new markets, thus leveraging and balancing R&D, sales, procurement and logistic synergies across several continents. Every subsidiary or a partner company successfully combines R&D, market evaluation and business development activities, and provides access to talents, innovations and market opportunities of the region.

BIOCAD will invest at least 3 billion rubles in a new production facility

biocad
BIOCAD, a biopharmaceutical company, will invest at least 3 billion rubles in the construction or upgrading of a pharmaceutical plant in Moscow

BIOСAD completes clinical trials of a biosimilar for anemia treatment

biocad
BIOСAD has completed the program of clinical trials for the first Russian-made darbepoetin alfa for the treatment of anemia in patients with chronic renal failure and oncological diseases

BIOCAD opens the Faculty of Molecular and Cell Biotechnology

research
On September 4, 2017, the students of the new Faculty began to attend their classes. This was preceded by a rigorous competitive selection, which revealed the best of the best.

BIOCAD will receive three land plots in St. Petersburg pharmaceutical cluster

biocad
BIOCAD, a biopharmaceutical company, will receive three land plots in the pharmaceutical cluster of Pushkinsky district.

Biocad comes to Egypt with an eye to the entire Middle Eastern market

biocad
Biocad, a Russian biotech company, plans to open its representative office in Egypt by the end of 2017

World’s largest library of human antibodies collected in Russia

biocad
The unique database includes more than 600 billion different molecules obtained from 1758 donors

Veronika Skvortsova – Russian vaccines are recognized globally

skvortsova v
In Russia, the original innovative medicines are being developed in all major medical fields

Authorities in India approved rituximab biosimilar produced by BIOCAD

biocad
The Central Drugs Standard Control Organization of India (CDSCO) approved for registration the first rituximab biosimilar fully manufactured by BIOCAD

BIOCAD opens the Department of Molecular and Cell Biotechnology

biocad-science-city
The new master's educational program is designed for university graduates who have already received their bachelor degree in biology or medicine.

BIOCAD will localize its manufacturing in Finland

biocad-fin
BIOCAD, a biotech company, is expanding its presence in international markets.

BIOCAD wins tender for the supply of Trastuzumab to Syria

biocad
This is the first tender which BIOCAD has won in Syria.

Russian biosimilars for rheumatic diseases will reduce the therapy costs

biocad
New products developed by BIOCAD, a Russian biotech company, can cut down by 30 to 50% the costs of annual treatment course with genetically engineered drugs for patients with rheumatic diseases. The ...

BIOCAD will continue to supply biosimilar of rituximab to Vietnam

biocad
In March, BIOCAD, a biotech company, has for the second time received a quota to supply a biosimilar of rituximab to Vietnam. This means that BIOCAD partners will continue to supply local hospitals wi...

BIOCAD launches a drug labeling information system

labelling
In mid-March, BIOCAD, a biotech company, launched in operating mode a Track&Trace system for its three products. This is a pilot project implemented as part of the experiment to label certain medi...

Pharmasyntez and Biocad are in top 10 Russian hospital procurement manufacturers

rusdrugs
According to the hospital audit of Russian pharmaceutical market conducted by DSM Group, in 2016, 882.2 million packages of medicinal products worth 221.9 billion rubles were purchased for hospitals i...

Equipment for labelling drugs will not cost more than 150,000 euros

druglabel
The cost of equipment required for labelling drugs on one production line of a pharmaceutical plant does not exceed €150,000. This was reported in an interview with TASS by Dmitry Morozov, General Dir...